Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo

Burnett, 2011, Current progress of siRNA/shRNA therapeutics in clinical trials, Biotechnol. J., 6, 1130, 10.1002/biot.201100054

Castanotto, 2009, The promises and pitfalls of RNA-interference-based therapeutics, Nature, 457, 426, 10.1038/nature07758

Chen, 2015, A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications, Nucl. Acids Res., 43, 3857, 10.1093/nar/gkv228

Dong, 2016, Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo, Nano Lett., 16, 842, 10.1021/acs.nanolett.5b02428

Duan, 2016, Bioengineered non-coding RNA agent (BERA) in action, Bioengineered, 7, 411, 10.1080/21655979.2016.1207011

Dunham, 2007, Recombinant RNA expression, Nat. Methods, 4, 547, 10.1038/nmeth0707-547

Ewe, 2016, Cationic lipid-coated polyplexes (lipopolyplexes) for DNA and small RNA delivery, Methods Mol. Biol., 1445, 187, 10.1007/978-1-4939-3718-9_12

Ewe, 2017, Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo, Nanomed. Nanotechnol. Biol. Med., 13, 209, 10.1016/j.nano.2016.08.005

He, 2016, Suppression of hepatic inflammation via systemic siRNA delivery by membrane-disruptive and endosomolytic helical polypeptide hybrid nanoparticles, Acs Nano, 10, 1859, 10.1021/acsnano.5b05470

Ho, 2016, Bioengineering of noncoding RNAs for research agents and therapeutics, Wiley Interdisciplinary Rev.-Rna, 7, 186, 10.1002/wrna.1324

Jayaraman, 2012, Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, Angew. Chem. Int. Ed., 51, 8529, 10.1002/anie.201203263

Jilek, 2017, Effects of MicroRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice, Drug Metab. Disp., 45, 512, 10.1124/dmd.116.074344

Kim, 2003, Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency, J. Pharm. Pharmacol., 55, 453, 10.1211/002235702928

Kranz, 2016, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature, 534, 396, 10.1038/nature18300

Kusumoto, 2013, Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium, Acs Nano, 7, 7534, 10.1021/nn401317t

Li, 2015, Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity, Drug Metab. Dispos., 43, 1129, 10.1124/dmd.115.064493

Li, 2014, Rapid production of novel Pre-MicroRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells, Drug Metab. Disp., 42, 1791, 10.1124/dmd.114.060145

Li, 2018, Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells, Drug Metab. Disp, 46, 2, 10.1124/dmd.117.078741

Maeda, 2004, Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome, J Control. Rel., 100, 41, 10.1016/j.jconrel.2004.07.033

Peng, 2017, Dual-function polymeric HPMA prodrugs for the delivery of miRNA, Mol. Pharmaceut., 14, 1395, 10.1021/acs.molpharmaceut.6b00999

Ponchon, 2007, Recombinant RNA technology: the tRNA scaffold, Nat. Methods, 4, 571, 10.1038/nmeth1058

Puri, 2009, Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic, Crit. Rev. Ther. Drug Carrier Syst., 26, 523, 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10

Sakurai, 2017, Efficient siRNA delivery by lipid nanoparticles modified with a nonstandard macrocyclic peptide for EpCAM-targeting, Mol. Pharmaceut., 14, 3290, 10.1021/acs.molpharmaceut.7b00362

Schafer, 2010, Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery, Biomaterials, 31, 6892, 10.1016/j.biomaterials.2010.05.043

Stepanov, 2015, In vivo production of small recombinant RNAs embedded in a 5S rRNA-derived protective scaffold, Rna Scaffolds, 1316, 45, 10.1007/978-1-4939-2730-2_5

Strumberg, 2012, Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors, Int. J. Clin. Pharmacol. Ther., 50, 76, 10.5414/CPP50076

Wang, 2015, Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization, J. Pharmacol. Exp. Ther., 354, 131, 10.1124/jpet.115.225631

Whitehead, 2009, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov., 8, 129, 10.1038/nrd2742

Xia, 2016, Effect of surface properties on liposomal siRNA delivery, Biomaterials, 79, 56, 10.1016/j.biomaterials.2015.11.056

Xue, 2015, Lipid-based nanocarriers for RNA delivery, Curr. Pharm. Des., 21, 3140, 10.2174/1381612821666150531164540

Yang, 2013, A nanoparticle formulation that selectively transfects metastatic tumors in mice, Proc. Natl. Acad. Sci., 110, 14717, 10.1073/pnas.1313330110

Zeng, 2017, PEGylated cationic vectors containing a protease-sensitive peptide as a miRNA delivery system for treating breast cancer, Mol. Pharmaceut., 14, 81, 10.1021/acs.molpharmaceut.6b00726

Zuckerman, 2015, Clinical experiences with systemically administered siRNA-based therapeutics in cancer, Nat. Rev. Drug Discov., 14, 843, 10.1038/nrd4685